Insider Selling: Gilead Sciences (NASDAQ:GILD) Insider Sells 3,000 Shares of Stock

Key Points

• Gilead Sciences insider Johanna Mercier sold 3,000 shares of stock on October 15th for a total of $354,240, reducing her ownership by 2.65% to 110,193 shares.
• The company reported Q2 earnings of $2.01 per share, exceeding analysts' estimates, with revenue of $7.08 billion for the quarter.
• Gilead recently announced a quarterly dividend of $0.79 per share, yielding approximately 2.7%, with a payout ratio of 62.95%.

Gilead Sciences, Inc. (NASDAQ:GILD - Get Free Report) insider Johanna Mercier sold 3,000 shares of the firm's stock in a transaction that occurred on Wednesday, October 15th. The stock was sold at an average price of $118.08, for a total transaction of $354,240.00. Following the sale, the insider owned 110,193 shares in the company, valued at $13,011,589.44. This trade represents a 2.65% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link.

Johanna Mercier also recently made the following trade(s):

• On Monday, September 15th, Johanna Mercier sold 3,000 shares of Gilead Sciences stock. The stock was sold at an average price of $113.57, for a total transaction of $340,710.00.
• On Friday, August 15th, Johanna Mercier sold 28,000 shares of Gilead Sciences stock. The shares were sold at an average price of $118.53, for a total transaction of $3,318,840.00.

Gilead Sciences Stock Down 0.4%

GILD traded down $0.45 during trading on Thursday, reaching $117.85. 6,742,459 shares of the stock were exchanged, compared to its average volume of 7,771,463. The stock has a market cap of $146.23 billion, a P/E ratio of 23.48, a price-to-earnings-growth ratio of 0.81 and a beta of 0.34. Gilead Sciences, Inc. has a twelve month low of $85.60 and a twelve month high of $121.83. The stock's 50 day moving average price is $115.15 and its two-hundred day moving average price is $110.45. The company has a debt-to-equity ratio of 1.13, a quick ratio of 1.15 and a current ratio of 1.32.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last issued its earnings results on Thursday, August 7th. The biopharmaceutical company reported $2.01 earnings per share for the quarter, topping analysts' consensus estimates of $1.96 by $0.05. The business had revenue of $7.08 billion for the quarter, compared to the consensus estimate of $6.95 billion. Gilead Sciences had a net margin of 21.86% and a return on equity of 50.99%. The firm's revenue for the quarter was up 1.4% on a year-over-year basis. During the same period in the previous year, the company earned $2.01 earnings per share. Gilead Sciences has set its FY 2025 guidance at 7.950-8.250 EPS. Equities analysts expect that Gilead Sciences, Inc. will post 7.95 EPS for the current year.

Gilead Sciences Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Monday, September 29th. Shareholders of record on Monday, September 15th were given a dividend of $0.79 per share. This represents a $3.16 dividend on an annualized basis and a yield of 2.7%. The ex-dividend date of this dividend was Monday, September 15th. Gilead Sciences's payout ratio is 62.95%.

Analyst Upgrades and Downgrades

GILD has been the subject of a number of research analyst reports. Cantor Fitzgerald lifted their price objective on shares of Gilead Sciences from $129.00 to $135.00 and gave the stock an "overweight" rating in a research report on Thursday, October 9th. Needham & Company LLC raised Gilead Sciences from a "hold" rating to a "buy" rating and set a $133.00 price target for the company in a research note on Friday, July 25th. UBS Group upped their price objective on Gilead Sciences from $108.00 to $112.00 and gave the company a "neutral" rating in a research note on Friday, August 8th. JPMorgan Chase & Co. upped their price objective on Gilead Sciences from $135.00 to $145.00 and gave the company an "overweight" rating in a research note on Tuesday, September 16th. Finally, Dbs Bank raised Gilead Sciences to a "moderate buy" rating in a research note on Friday, September 5th. Two investment analysts have rated the stock with a Strong Buy rating, twenty-one have issued a Buy rating and six have assigned a Hold rating to the stock. According to data from MarketBeat, the company has an average rating of "Moderate Buy" and an average price target of $118.08.

Hedge Funds Weigh In On Gilead Sciences

Institutional investors have recently modified their holdings of the company. One Wealth Advisors LLC raised its position in shares of Gilead Sciences by 34.8% during the second quarter. One Wealth Advisors LLC now owns 9,163 shares of the biopharmaceutical company's stock worth $1,016,000 after purchasing an additional 2,364 shares during the period. Ariel Investments LLC raised its position in Gilead Sciences by 7.7% in the 1st quarter. Ariel Investments LLC now owns 430,424 shares of the biopharmaceutical company's stock valued at $48,229,000 after buying an additional 30,630 shares during the last quarter. Golden State Wealth Management LLC raised its position in Gilead Sciences by 14.5% in the 1st quarter. Golden State Wealth Management LLC now owns 863 shares of the biopharmaceutical company's stock valued at $97,000 after buying an additional 109 shares during the last quarter. Covea Finance raised its position in Gilead Sciences by 69.5% in the 2nd quarter. Covea Finance now owns 51,700 shares of the biopharmaceutical company's stock valued at $5,732,000 after buying an additional 21,200 shares during the last quarter. Finally, Swedbank AB raised its position in Gilead Sciences by 0.8% in the 1st quarter. Swedbank AB now owns 2,118,632 shares of the biopharmaceutical company's stock valued at $237,393,000 after buying an additional 16,663 shares during the last quarter. 83.67% of the stock is owned by institutional investors and hedge funds.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.